The European Commission has approved Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic and extra-pancreatic neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.
An updated clinical guideline from the American Society for Radiation Oncology provides evidence-based recommendations on the use of radiation therapy to treat adult patients with pancreatic cancer.
